Background: Tocilizumab (TCZ) is a recombinant humanized, anti-human monoclonal antibody of the immunoglobulin G1 k subclass directed against soluble IL-6R, Hum Vaccin Immunother. 2017;13(9):1972–1988.

Methods: With an increasing usage of non-TNFI biologics and tofacitinib, it is crucial to understand the comparative safety of these agents regarding malignancies risk.

Disclosures of Interests: Francisco Vilches-Oya: None declared, Ana Pros: None declared, Irene Carrión Barberà: Grant/research support from: I received a grant from the Spanish Rheumatology Foundation (FER) and laboratories KERN PHARMA for a brief stay abroad., Juan Antonio Meraz Ostiz: None declared, Tarek Carlos Salmon Monte: None declared, Carolina Perez-Garcia: None declared

Disclosure of Interests: None declared

References:


Disclosure of Interests: Francisco Vilches-Oya: None declared, Ana Pros: None declared, Irene Carrión Barberà: Grant/research support from: I received a grant from the Spanish Rheumatology Foundation (FER) and laboratories KERN PHARMA for a brief stay abroad., Juan Antonio Meraz Ostiz: None declared, Tarek Carlos Salmon Monte: None declared, Carolina Perez-Garcia: None declared

Disclosure of Interests: None declared

References:


Disclosure of Interests: Francisco Vilches-Oya: None declared, Ana Pros: None declared, Irene Carrión Barberà: Grant/research support from: I received a grant from the Spanish Rheumatology Foundation (FER) and laboratories KERN PHARMA for a brief stay abroad., Juan Antonio Meraz Ostiz: None declared, Tarek Carlos Salmon Monte: None declared, Carolina Perez-Garcia: None declared

Disclosure of Interests: None declared

References: